250 related articles for article (PubMed ID: 16178779)
1. Novel approaches towards development of non-classical platinum-based antineoplastic agents: design of platinum complexes characterized by an alternative DNA-binding pattern and/or tumor-targeted cytotoxicity.
Momekov G; Bakalova A; Karaivanova M
Curr Med Chem; 2005; 12(19):2177-91. PubMed ID: 16178779
[TBL] [Abstract][Full Text] [Related]
2. Nonclassical platinum antitumor agents: perspectives for design and development of new drugs complementary to cisplatin.
Farrell N
Cancer Invest; 1993; 11(5):578-89. PubMed ID: 8402226
[TBL] [Abstract][Full Text] [Related]
3. New platinum antitumor complexes.
Kelland LR
Crit Rev Oncol Hematol; 1993 Dec; 15(3):191-219. PubMed ID: 8142057
[TBL] [Abstract][Full Text] [Related]
4. Preparation and characterization of platinum(II) and (IV) complexes of 1,3-diaminepropane and 1,4-diaminebutane: circumvention of cisplatin resistance and DNA interstrand cross-link formation in CH1cisR ovarian tumor cells.
Alvarez-Valdés A; Pérez JM; López-Solera I; Lannegrand R; Continente JM; Amo-Ochoa P; Camazón MJ; Solans X; Font-Bardía M; Navarro-Ranninger C
J Med Chem; 2002 Apr; 45(9):1835-44. PubMed ID: 11960495
[TBL] [Abstract][Full Text] [Related]
5. [Drug discovery research in in-vivo antitumor-active azolato-bridged dinuclear Pt(II) complexes].
Komeda S
Yakugaku Zasshi; 2012; 132(3):253-9. PubMed ID: 22382827
[TBL] [Abstract][Full Text] [Related]
6. Dinuclear Platinum(II) Complexes with Bone-Targeting Groups as Potential Anti-Osteosarcoma Agents.
Zhang Z; Wang X; Luo C; Zhu C; Wang K; Zhang C; Guo Z
Chem Asian J; 2017 Jul; 12(13):1659-1667. PubMed ID: 28556606
[TBL] [Abstract][Full Text] [Related]
7. A novel trans-platinum coordination complex possessing in vitro and in vivo antitumor activity.
Kelland LR; Barnard CF; Mellish KJ; Jones M; Goddard PM; Valenti M; Bryant A; Murrer BA; Harrap KR
Cancer Res; 1994 Nov; 54(21):5618-22. PubMed ID: 7923207
[TBL] [Abstract][Full Text] [Related]
8. Fresh platinum complexes with promising antitumor activity.
Wang X
Anticancer Agents Med Chem; 2010 Jun; 10(5):396-411. PubMed ID: 20545618
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and in vitro and in vivo antitumor activity of a series of trans platinum antitumor complexes.
Kelland LR; Barnard CF; Evans IG; Murrer BA; Theobald BR; Wyer SB; Goddard PM; Jones M; Valenti M; Bryant A
J Med Chem; 1995 Aug; 38(16):3016-24. PubMed ID: 7636864
[TBL] [Abstract][Full Text] [Related]
10. Antitumor activity of a new platinum(II) complex with low nephrotoxicity and genotoxicity.
Marzano C; Bettio F; Baccichetti F; Trevisan A; Giovagnini L; Fregona D
Chem Biol Interact; 2004 Jun; 148(1-2):37-48. PubMed ID: 15223355
[TBL] [Abstract][Full Text] [Related]
11. DNA binding mode of ruthenium complexes and relationship to tumor cell toxicity.
Brabec V; Nováková O
Drug Resist Updat; 2006 Jun; 9(3):111-22. PubMed ID: 16790363
[TBL] [Abstract][Full Text] [Related]
12. DNA binding mode of the cis and trans geometries of new antitumor nonclassical platinum complexes containing piperidine, piperazine, or 4-picoline ligand in cell-free media. Relations to their activity in cancer cell lines.
Kasparkova J; Marini V; Najajreh Y; Gibson D; Brabec V
Biochemistry; 2003 May; 42(20):6321-32. PubMed ID: 12755637
[TBL] [Abstract][Full Text] [Related]
13. [Current status of and future perspectives for platinum antitumor drugs].
Chikuma M; Sato T; Komeda S
Yakugaku Zasshi; 2008 Mar; 128(3):307-16. PubMed ID: 18311048
[TBL] [Abstract][Full Text] [Related]
14. Novel concepts in the development of platinum antitumor drugs.
Fuertes MA; Castilla J; Alonso C; Pérez JM
Curr Med Chem Anticancer Agents; 2002 Jul; 2(4):539-51. PubMed ID: 12678734
[TBL] [Abstract][Full Text] [Related]
15. trans-Dichloridopalladium(II) and platinum(II) complexes with 2-(hydroxymethyl)pyridine and 2-(2-hydroxyethyl)pyridine: synthesis, structural characterization, DNA binding and in vitro cytotoxicity studies.
Icsel C; Yilmaz VT; Ari F; Ulukaya E; Harrison WT
Eur J Med Chem; 2013 Feb; 60():386-94. PubMed ID: 23314052
[TBL] [Abstract][Full Text] [Related]
16. Novel bis-platinum complexes endowed with an improved pharmacological profile.
Gatti L; Perego P; Leone R; Apostoli P; Carenini N; Corna E; Allievi C; Bastrup U; De Munari S; Di Giovine S; Nicoli P; Grugni M; Natangelo M; Pardi G; Pezzoni G; Singer JW; Zunino F
Mol Pharm; 2010 Feb; 7(1):207-16. PubMed ID: 19919086
[TBL] [Abstract][Full Text] [Related]
17. Platinum-based drugs: past, present and future.
Dilruba S; Kalayda GV
Cancer Chemother Pharmacol; 2016 Jun; 77(6):1103-24. PubMed ID: 26886018
[TBL] [Abstract][Full Text] [Related]
18. Comparative studies on the mechanism of cytotoxic action of novel platinum II complexes with pyrazole ligands.
Ciesielska E; Szulawska A; Studzian K; Ochocki J; Malinowska K; Kik K; Szmigiero L
J Inorg Biochem; 2006 Oct; 100(10):1579-85. PubMed ID: 16842854
[TBL] [Abstract][Full Text] [Related]
19. Targeting drug delivery system for platinum(Ⅳ)-Based antitumor complexes.
Zhong Y; Jia C; Zhang X; Liao X; Yang B; Cong Y; Pu S; Gao C
Eur J Med Chem; 2020 May; 194():112229. PubMed ID: 32222677
[TBL] [Abstract][Full Text] [Related]
20. Synthesis, characterization, and biological evaluation of new tetrazole-based platinum(II) and palladium(II) chlorido complexes--potent cisplatin analogues and their trans isomers.
Serebryanskaya TV; Yung T; Bogdanov AA; Shchebet A; Johnsen SA; Lyakhov AS; Ivashkevich LS; Ibrahimava ZA; Garbuzenco TS; Kolesnikova TS; Melnova NI; Gaponik PN; Ivashkevich OA
J Inorg Biochem; 2013 Mar; 120():44-53. PubMed ID: 23305964
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
